Prostate Cancer Management with Multimodality Imaging

描述（由申请人提供）：除了传统的结构成像技术、计算机断层扫描（CT）、磁共振成像（MRI）和经直肠超声检查（TRUS）之外，非侵入性成像技术在前列腺癌治疗方面取得了实质性进展，包括放射性核素成像和磁共振波谱成像（MRSI）。然而，没有任何一种成像技术能够证明评估前列腺癌所需的广泛功能。此外，尚未建立使用这些现有成像技术的连贯多模态方法来治疗这种疾病。因此，我们建议开发一种方法，为同一患者提供一套全面的功能、代谢、生物分子和结构成像模式，以改善前列腺癌患者的治疗。该项目的目标是开发一种结合多种成像方式信息的方法，并开发一种方法来改善当前治疗前和治疗后病例中的前列腺癌管理。在本研究中，我们将在项目初期重点研究使用铟-111放射性标记单克隆抗体和 MRI/MRSI 技术的双模态 SPECT/CT 成像。 目标 1：将开发一种方法，利用商用 SPECT/CT 系统（Discovery VH Hawkeye，GE Healthcare，Waukesha，WI）量化模型和患者中 111ln 标记的 capromab pendetide（ProstaScint(R)，Cytogen Corporation，Princeton，NJ）的活性。随后，量化 111ln-ProstaScint(R) 摄取的方法将扩展到结合 SPECT/CT 和 MRI/MRSI 来评估前列腺癌的方法。 目标 2：我们将开发关联 SPECT/CT 和 MRI/MRSI 图像的方法，以评估患有转移性癌症的高风险患者，以协助制定放射治疗计划。根据目标 1 和 2 开发的 111ln-ProstaScint(R)SPECT/CT 和 MRI/MRSI 研究的定量测量和相关性可以指导目标 3 下实施的放射治疗计划。 目标 3：将开发一种在放射治疗计划中实现相关图像呈现的方法。 我们相信，成功完成拟议研究计划的结果不仅将增强临床前列腺癌管理，而且还将为候选人提供宝贵的能力技能和知识，使其成为具有强大定量科学背景的独立生物医学研究员。

DESCRIPTION (provided by applicant): Substantial advances in prostate cancer management have been made with noninvasive imaging techniques including radionuclide imaging and magnetic resonance spectroscopy imaging (MRSI) in addition to conventional structural imaging techniques, computed tomography (CT), magnetic resonance imaging (MRI), and transrectal ultrasonography (TRUS). However, no single imaging technique has demonstrated the breadth of functionality needed to assess prostate cancer. In addition, a coherent multimodality approach using these already available imaging techniques has not been established for the clinical management of this disease. We therefore propose to develop an approach to present a comprehensive set of functional, metabolic, biomolecular, and structural imaging modalities for the same patient to improve management of patients with prostate cancer. The goal of this project is to develop an approach that combines information from multiple imaging modalities and to develop a method to improve the current prostate cancer management in both pretherapy and posttherapy cases. In this study, we will focus on the dual-modality SPECT/CT imaging using an indium-111 radiolabeled monoclonal antibody and MRI/MRSI techniques during initial periods of the project. Goal 1: A method will be developed to quantify 111ln-labeled capromab pendetide (ProstaScint(R), Cytogen Corporation, Princeton, NJ) activity in phantoms and patients with a commercial SPECT/CT system (Discovery VH Hawkeye, GE Healthcare, Waukesha, Wl). The methods of quantifying 111ln-ProstaScint(R) uptake then will be extended to an approach that combines SPECT/CT and MRI/MRSI for assessment of prostate cancer. Goal 2: We will develop methods that correlate SPECT/CT and MRI/MRSI images to evaluate patients at a high risk of having metastasized cancer with a goal of assisting radiation treatment planning. The quantitative measurements and correlations from 111ln-ProstaScint( R)SPECT/CT and MRI/MRSI studies developed from Goal 1 and 2 then can guide radiation therapy planning which will be pursued under Goal 3. Goal 3: A method to implement the correlative image presentation in radiation treatment planning will be developed. We believe that outcomes from the successful completion of the proposed research program will not only enhance the clinical prostate cancer management but also provide valuable aptitude skills and knowledge for the candidate to become an independent biomedical researcher with strong background in quantitative sciences.